The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung Cancer

被引:6
作者
Sakaguchi, Tadashi [1 ]
Iketani, Akemi [2 ]
Esumi, Seiya [1 ]
Esumi, Maki [1 ]
Suzuki, Yuta [1 ]
Ito, Kentaro [1 ]
Fujiwara, Kentaro [1 ]
Nishii, Yoichi [1 ]
Katsuta, Koji [2 ]
Yasui, Hiroki [1 ]
Taguchi, Osamu [1 ]
Hataji, Osamu [1 ]
机构
[1] Matsusaka Municipal Hosp, Dept Resp Med, 1550,Tonomachi, Matsusaka, Mie 5150073, Japan
[2] Matsusaka Municipal Hosp, Pathol Dept, 1550,Tonomachi, Matsusaka, Mie 5150073, Japan
关键词
Amoy Dx (R) Pan Lung Cancer PCR panel; multi-gene panel test; next-generation sequencing; non-small-cell lung cancer; Oncomine Dx Target Test; DX TARGET TEST; PERCENTAGE;
D O I
10.3390/cancers16091670
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some multi-gene panel tests have been implemented in clinical settings to guide targeted therapy in non-small-cell lung cancer (NSCLC) in Japan. The current performance of multi-gene panel tests under the condition that the Oncomine Dx Target Test (ODxTT) and Amoy Dx (R) Pan Lung Cancer PCR panel (AmoyDx-multi) are available remains relatively unknown. We retrospectively reviewed consecutive patients with NSCLC, whose FFPE samples were considered for genetic testing. We assessed the submission rates, the success rates, and the driver oncogene detection rates of multi-gene panel tests. A total of 225 patients were histologically newly diagnosed with NSCLC or diagnosed with a recurrence of NSCLC without a previous multi-gene panel test at our institution. Among the 225 patients, the FFPE samples of 212 patients (94.2%) were submitted for multi-gene panel testing, including 191 samples (84.9%) for the ODxTT and 21 samples (9.3%) for the AmoyDx-multi. Among the 212 samples submitted to multi-gene panel tests, the success rate was 99.5% (211/212). The detection rate of driver oncogene alterations for all histologies was 52.4% (111/212), and that for adenocarcinoma was 69.7% (106/152). A favorable submission rate and success rate of multi-gene panel tests were shown, along with a favorable detection rate in recent clinical settings.
引用
收藏
页数:11
相关论文
共 32 条
[1]   Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience [J].
Dall'Olio, Filippo G. ;
Conci, Nicole ;
Rossi, Giulio ;
Fiorentino, Michelangelo ;
De Giglio, Andrea ;
Grilli, Giada ;
Altimari, Annalisa ;
Gruppioni, Elisa ;
Filippini, Daria M. ;
Di Federico, Alessandro ;
Nuvola, Giacomo ;
Ardizzoni, Andrea .
LUNG CANCER, 2020, 149 :5-9
[2]  
Food and Drug Administration, 2017, Summary of Safety and Effectiveness Data
[3]   Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].
Forde, Patrick M. ;
Spicer, Jonathan ;
Lu, Shun ;
Provencio, Mariano ;
Mitsudomi, Tetsuya ;
Awad, Mark M. ;
Felip, Enriqueta ;
Broderick, Stephen R. ;
Brahmer, Julie R. ;
Swanson, Scott J. ;
Kerr, Keith ;
Wang, Changli ;
Ciuleanu, Tudor-Eliade ;
Saylors, Gene B. ;
Tanaka, Fumihiro ;
Ito, Hiroyuki ;
Chen, Ke-Neng ;
Liberman, Moishe ;
Vokes, Everett E. ;
Taube, Janis M. ;
Dorange, Cecile ;
Cai, Junliang ;
Fiore, Joseph ;
Jarkowski, Anthony ;
Balli, David ;
Sausen, Mark ;
Pandya, Dimple ;
Calvet, Christophe Y. ;
Girard, Nicolas .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985
[4]  
Hatanaka Y, 2022, Haigan, V62, P15, DOI [10.2482/haigan.62.15, 10.2482/haigan.62.15, DOI 10.2482/HAIGAN.62.15]
[5]   The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine [J].
Hatanaka, Yutaka ;
Kuwata, Takeshi ;
Morii, Eiichi ;
Kanai, Yae ;
Ichikawa, Hitoshi ;
Kubo, Takashi ;
Hatanaka, Kanako C. ;
Sakai, Kazuko ;
Nishio, Kazuto ;
Fujii, Satoshi ;
Okamoto, Wataru ;
Yoshino, Takayuki ;
Ochiai, Atsushi ;
Oda, Yoshinao .
PATHOLOGY INTERNATIONAL, 2021, 71 (11) :725-740
[6]   Possible False Results With cobas® EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation [J].
Kanaoka, Kensuke ;
Tamiya, Akihiro ;
Inagaki, Yuji ;
Taniguchi, Yoshihiko ;
Nakao, Keiko ;
Takeda, Maiko ;
Matsuda, Yoshinobu ;
Okishio, Kyoichi ;
Shimizu, Shigeki .
ANTICANCER RESEARCH, 2023, 43 (06) :2771-2776
[7]   Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non- small Cell Lung Cancer [J].
Kanasaki, Hiroki ;
Ozawa, Yuichi ;
Nakamura, Naoto ;
Nagasaki, Kimihiko ;
Matsuyama, Wataru ;
Akahori, Daisuke ;
Niwa, Mitsuru ;
Ogasawara, Takashi ;
Sato, Jun .
ANTICANCER RESEARCH, 2024, 44 (02) :723-730
[8]   Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs [J].
Kris, Mark G. ;
Johnson, Bruce E. ;
Berry, Lynne D. ;
Kwiatkowski, David J. ;
Iafrate, A. John ;
Wistuba, Ignacio I. ;
Varella-Garcia, Marileila ;
Franklin, Wilbur A. ;
Aronson, Samuel L. ;
Su, Pei-Fang ;
Shyr, Yu ;
Camidge, D. Ross ;
Sequist, Lecia V. ;
Glisson, Bonnie S. ;
Khuri, Fadlo R. ;
Garon, Edward B. ;
Pao, William ;
Rudin, Charles ;
Schiller, Joan ;
Haura, Eric B. ;
Socinski, Mark ;
Shirai, Keisuke ;
Chen, Heidi ;
Giaccone, Giuseppe ;
Ladanyi, Marc ;
Kugler, Kelly ;
Minna, John D. ;
Bunn, Paul A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (19) :1998-2006
[9]   Clinical application of the AMOY 9-in-1 panel to lung cancer patients [J].
Kunimasa, Kei ;
Matsumoto, Shingo ;
Kawamura, Takahisa ;
Inoue, Takako ;
Tamiya, Motohiro ;
Kanzaki, Ryu ;
Maniwa, Tomohiro ;
Okami, Jiro ;
Honma, Keiichiro ;
Goto, Koichi ;
Nishino, Kazumi .
LUNG CANCER, 2023, 179
[10]   Improvement strategies for successful next-generation sequencing analysis of lung cancer [J].
Kunimasa, Kei ;
Matsumoto, Shingo ;
Nishino, Kazumi ;
Nakamura, Harumi ;
Kuhara, Hanako ;
Tamiya, Motohiro ;
Inoue, Takako ;
Kawamura, Takahisa ;
Kawachi, Hayato ;
Kuno, Kika ;
Kimura, Toru ;
Maniwa, Tomohiro ;
Okami, Jiro ;
Nakatsuka, Shin-ichi ;
Goto, Koichi ;
Kumagai, Toru .
FUTURE ONCOLOGY, 2020, 16 (22) :1597-+